Intra-Cellular Therapies to Present at 2019 RBC Capital Markets Global Healthcare Conference
May 16 2019 - 8:00AM
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical
company focused on the development of therapeutics for central
nervous system (CNS) disorders, today announced that Sharon
Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to
present at the 2019 RBC Capital Markets Global Healthcare
Conference in New York. The presentation is scheduled
for Wednesday, May 22, 2019 at 11:00 am ET.
The live and archived webcast can be accessed under "Press
Releases & Events" in the Investor Relations section of the
Company's website at www.intracellulartherapies.com. Please
log in approximately 5-10 minutes prior to the event to register
and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the
treatment of neuropsychiatric and neurodegenerative diseases and
diseases of the elderly, including Parkinson's and Alzheimer's
disease. The Company is developing its lead drug candidate,
lumateperone (also known as ITI-007), for the treatment of
schizophrenia, bipolar disorder, behavioral disturbances in
patients with dementia, including Alzheimer's disease, depression
and other neuropsychiatric and neurological disorders.
Lumateperone is under review by the FDA for the
treatment of schizophrenia and is in Phase 3 clinical development
for the treatment of bipolar depression. The Company is also
utilizing its phosphodiesterase (PDE) platform and other
proprietary chemistry platforms to develop drugs for the treatment
of CNS and other disorders. The lead molecule in the Company's PDE1
portfolio, ITI-214, is in development for the treatment of symptoms
associated with Parkinson's disease and for the treatment of heart
failure.
Contact:
Intra-Cellular Therapies, Inc. Juan Sanchez, M.D. Vice
President, Corporate Communications and Investor Relations
646-440-9333
Burns McClellan, Inc. Lisa Burns agray@burnsmc.com
212-213-0006
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Apr 2023 to Apr 2024